Cargando…

Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria

SETTING: Nigeria adopted GeneXpert MTB Rif as a primary diagnostic tool were available and accessible since 2016. The current geographical coverage of GeneXpert machines by LGAs stands at 48%, with a varied access and utilization. OBJECTIVES: To assess the association between the type and level of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Gidado, Mustapha, Nwokoye, Nkiru, Ogbudebe, Chidubem, Nsa, Bassey, Nwadike, Peter, Ajiboye, Prisca, Eneogu, Rupert, Useni, Sani, Elom, Emeka, Lawanson, Adebola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677003/
https://www.ncbi.nlm.nih.gov/pubmed/31413433
http://dx.doi.org/10.4103/nmj.NMJ_12_19
_version_ 1783440866427273216
author Gidado, Mustapha
Nwokoye, Nkiru
Ogbudebe, Chidubem
Nsa, Bassey
Nwadike, Peter
Ajiboye, Prisca
Eneogu, Rupert
Useni, Sani
Elom, Emeka
Lawanson, Adebola
author_facet Gidado, Mustapha
Nwokoye, Nkiru
Ogbudebe, Chidubem
Nsa, Bassey
Nwadike, Peter
Ajiboye, Prisca
Eneogu, Rupert
Useni, Sani
Elom, Emeka
Lawanson, Adebola
author_sort Gidado, Mustapha
collection PubMed
description SETTING: Nigeria adopted GeneXpert MTB Rif as a primary diagnostic tool were available and accessible since 2016. The current geographical coverage of GeneXpert machines by LGAs stands at 48%, with a varied access and utilization. OBJECTIVES: To assess the association between the type and level of health facilities implementing GeneXpert MTB/Rif and performance outcome of the machines in Nigeria. STUDY DESIGN: Retrospective secondary data analysis of GeneXpert performance for 2017 from GXAlert database. The independent variables were type and levels of health care facilities, and dependent variables were GeneXpert performance (utilization, successful test, error rates, MTB detected, and Rifampicin resistance detected). RESULTS: Only 366 health care facilities are currently implementing and reporting GeneXpert performance, the distribution is 86.9% and 13.1% public and private health care facilities respectively, and only 6.3% of the facilities are primary health care. Of 354,321 test conducted in 2017, 91.5% were successful, and among unsuccessful test 6.8% were errors. The yield was 16.8% MTB detected (54,713) among which 6.8% had Rif resistance. The GeneXpert utilization rate was higher among private health care facilities (55.8%) compared to 33.3% among public health care facilities. There was a statistically significant difference in the number of successful test between public and private health facility-based machines as determined by one-way ANOVA (F(1,2) = 21.81, P = 0.02) and between primary, secondary and tertiary level health facility-based machines (F(1,2) = 41.24, P < 0.01). CONCLUSION: Nigeria with very low TB coverage should rapidly scale-up and decentralize GeneXpert services to the private sector.
format Online
Article
Text
id pubmed-6677003
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-66770032019-08-14 Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria Gidado, Mustapha Nwokoye, Nkiru Ogbudebe, Chidubem Nsa, Bassey Nwadike, Peter Ajiboye, Prisca Eneogu, Rupert Useni, Sani Elom, Emeka Lawanson, Adebola Niger Med J Original Article SETTING: Nigeria adopted GeneXpert MTB Rif as a primary diagnostic tool were available and accessible since 2016. The current geographical coverage of GeneXpert machines by LGAs stands at 48%, with a varied access and utilization. OBJECTIVES: To assess the association between the type and level of health facilities implementing GeneXpert MTB/Rif and performance outcome of the machines in Nigeria. STUDY DESIGN: Retrospective secondary data analysis of GeneXpert performance for 2017 from GXAlert database. The independent variables were type and levels of health care facilities, and dependent variables were GeneXpert performance (utilization, successful test, error rates, MTB detected, and Rifampicin resistance detected). RESULTS: Only 366 health care facilities are currently implementing and reporting GeneXpert performance, the distribution is 86.9% and 13.1% public and private health care facilities respectively, and only 6.3% of the facilities are primary health care. Of 354,321 test conducted in 2017, 91.5% were successful, and among unsuccessful test 6.8% were errors. The yield was 16.8% MTB detected (54,713) among which 6.8% had Rif resistance. The GeneXpert utilization rate was higher among private health care facilities (55.8%) compared to 33.3% among public health care facilities. There was a statistically significant difference in the number of successful test between public and private health facility-based machines as determined by one-way ANOVA (F(1,2) = 21.81, P = 0.02) and between primary, secondary and tertiary level health facility-based machines (F(1,2) = 41.24, P < 0.01). CONCLUSION: Nigeria with very low TB coverage should rapidly scale-up and decentralize GeneXpert services to the private sector. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6677003/ /pubmed/31413433 http://dx.doi.org/10.4103/nmj.NMJ_12_19 Text en Copyright: © 2019 Nigerian Medical Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gidado, Mustapha
Nwokoye, Nkiru
Ogbudebe, Chidubem
Nsa, Bassey
Nwadike, Peter
Ajiboye, Prisca
Eneogu, Rupert
Useni, Sani
Elom, Emeka
Lawanson, Adebola
Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title_full Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title_fullStr Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title_full_unstemmed Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title_short Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria
title_sort assessment of genexpert mtb/rif performance by type and level of health-care facilities in nigeria
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677003/
https://www.ncbi.nlm.nih.gov/pubmed/31413433
http://dx.doi.org/10.4103/nmj.NMJ_12_19
work_keys_str_mv AT gidadomustapha assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT nwokoyenkiru assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT ogbudebechidubem assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT nsabassey assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT nwadikepeter assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT ajiboyeprisca assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT eneogurupert assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT usenisani assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT elomemeka assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria
AT lawansonadebola assessmentofgenexpertmtbrifperformancebytypeandlevelofhealthcarefacilitiesinnigeria